Transarterial embolization in non-cavernous and cavernous sinus dural arteriovenous fistulas: A systematic review and meta-analysis of proportions.

ABSTRACT

BACKGROUND: Transarterial embolization (TAE) is pivotal in managing non-cavernous and cavernous sinus dural arteriovenous fistulas (CSDAVFs). METHODS: Systematic searches were conducted across ScienceDirect, Medline, and Cochrane databases for longitudinal studies on TAE outcomes in non-CSDAVFs and CSDAVFs. Post-procedural outcomes, including complete, incomplete, and failed AVFs obliteration, and end-study outcomes were analyzed. RESULTS: Our meta-analysis involved 27 studies with 643 patients and 736 fistulas. Symptoms in both groups included tinnitus (29.74 %), ocular/visual symptoms (29.12 %), hemorrhage (19.42 %), and headache (19.11 %). Feeding arteries mainly originated from the meningeal arteries (49.16 %). In non-CSDAVFs cases, fistula locations were within sinus complexes (69.23 %) and specific dural areas (28.31 %). Complete AVFs obliteration was 81 % (95 %CI 70 % - 90 %), slightly higher in non-CSDAVFs (82 %, 95 % CI 69 % - 92 %) than CSDAVFs (79 %, 95 %CI 58 % - 95 %). Incomplete obliteration occurred in 14 % (95 %CI 5 % - 39 %), with rates of 11 % (95 %CI 2 % - 26 %) in non-CSDAVFs and 19 % (95 % CI 5 % - 39 %) in CSDAVFs. Failed obliteration was rare (1 %, 95 %CI 0 % - 3 %), with similar rates in both groups. At end-study follow-up, resolution of AVFs was achieved in 97 % of cases (95 %CI 92 % - 100 %). However, complications occurred in 17 % of cases (95 %CI 10 % - 25 %), with a higher incidence in CSDAVFs (22 %, 95 %CI 9 % - 37 %) compared to non-CSDAVFs (13 %, 95 %CI 6 % - 23 %). CONCLUSIONS: TAE with embolic agents demonstrates favorable outcomes in non-CSDAVFs and CSDAVFs, with high rates of AVFs obliteration and resolution. Complications, particularly in CSDAVFs, warrant careful consideration in treatment decisions.